Pharsight

Drugs that contain Etelcalcetide

1. Parsabiv patents expiration

PARSABIV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9278995 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(6 years from now)

US8377880 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(6 years from now)

US9701712 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(6 years from now)

US8999932 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Feb, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11162500 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(10 years from now)

US9820938 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(10 years from now)

US10344765 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

NCE-1 date: 2021-02-07

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's drug patent expiration?
More Information on Dosage

PARSABIV family patents

Family Patents